MAPT and Alzheimer disease: Currently, Alzheimer’s disease (AD) diagnostics rely on cognitive testing supported by additional biomarkers, which include cerebrospinal fluid Aβ42, total and phosphorylated full-length-tau or its truncated form, positron emission tomography (PET) of brain amyloid deposition and glucose metabolism, and brain atrophy on MRI (Cross et al., 2007; Battisti et al., 2012; Okamura et al., 2014; Brier et al., 2016; Florenzano et al., 2017; Wojsiat et al., 2017).